BLOG/πŸ‡ΊπŸ‡ΈUnited StatesΒ·Β·daily

All HHS Contracts β€” February 06, 2026

All HHS Contracts

4 total filings analysed

Executive Summary

HHS contracts totaling $348M obligated highlight robust demand for health IT services (75% of value), with Deloitte capturing 50% ($174.6M) across NIH and FDA wins amid modernization efforts. High outlays (avg. 85% disbursed) across all awards signal strong execution and revenue visibility through 2026-2031. Bullish for large-cap IT integrators and niche medical providers, with options adding $410M+ upside potential.

Tracking the trend? Catch up on the prior All HHS Contracts digest from February 05, 2026.

Investment Signals(3)

  • Deloitte dominates HHS IT with $174.6M obligated(HIGH)
    β–²

    Two awards (NIH UFMS $88.5M, FDA CBER $86.1M) represent 50% of period value, with 92% avg. outlay and potential to $419M incl. options.

  • Health IT sector secures 75% of HHS spend ($261M)(HIGH)
    β–²

    NIH, FDA, CMS awards under NAICS 541512/541519 for systems integration/modernization signal sustained federal demand through 2031.

  • E3Health locks $101M CDC medical support revenue(HIGH)
    β–²

    100% outlay on 3.4-year firm-fixed award to Woman-Owned SBE underscores small business access to large CDC needs.

Risk Flags(2)

  • Execution[HIGH RISK]
    β–Ό

    Long performance periods (to 2031 for Deloitte NIH) with avg. $12M remaining obligations expose delays/subcontractor issues (e.g., 39 FDA subs at $12M).

  • Competitive[MEDIUM RISK]
    β–Ό

    Firm-fixed pricing across 75% of value risks margin erosion if costs exceed estimates; no set-asides limit small biz renewals post-2025.

Opportunities(2)

  • β—†

    $410M+ in unexercised options (Deloitte NIH $245M, others $6-7M) could boost total value 118%.

  • β—†

    Recurring HHS IT modernization (UFMS, CBER, claims processing) and CDC medical support position winners for follow-ons post-2024-2026 expirations.

Sector Themes(2)

  • β—†

    75% of value targets systems integration/hosting (NAICS 541512/541519) across NIH/FDA/CMS, with Deloitte/GDIT leading.

  • β—†

    50% to large firms, 29% to small biz (E3Health), blending IT (75%) and medical support.

Watch List(3)

  • πŸ‘

    {"entity"=>"Deloitte Consulting LLP", "reason"=>"50% value share with $245M NIH options and 2031 potential", "trigger"=>"Option exercises or new HHS IT awards"}

  • πŸ‘

    {"entity"=>"E3Health Solutions LLC", "reason"=>"$101M fully outlayed CDC award ends 2025-11-30", "trigger"=>"Follow-on CDC medical support contracts"}

  • πŸ‘

    {"entity"=>"HHS IT End Dates (2024-2026)", "reason"=>"3 contracts expire soon with $16M remaining obligations", "trigger"=>"Recompetes or extensions"}

Get daily alerts with 3 investment signals, 2 risk alerts, 2 opportunities and full AI analysis of all 4 filings

πŸ‡ΊπŸ‡Έ More from United States

View all β†’
All HHS Contracts β€” February 06, 2026 | Gunpowder Blog